Skip to content
JOURNAL OFBIOHACKING

Nutrigenomics

Plain reading copy. The complete dossier, sources and answer disclosures work without JavaScript.

Open interactive reader All plain dossiers

Use the interactive reader for saved reading, notes and progress. Source check dates and scope are reproduced from the existing record; elapsed-time reminders are omitted. Glossary definitions also work without JavaScript; interactive search and personal tools require it.

genomics · experimental

Reference snapshot

Evidence gradeC
Linked records4
Coverage lanePrimary human evidence
Last source check2026-08-17

This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.

Claim ledger

Support not yet mapped. These editorial statements retain their original wording; related topic sources are available separately and have not been assigned as claim-specific support.

Signal

Nutrigenomics has clear promise in subgroup interpretation but limited direct consumer generalizability.

Support not yet mapped

Boundary

Variable by trait, ancestry data quality, and outcome specificity.

Support not yet mapped

Not established

Linked records do not establish a universal nutrigenomics protocol, diagnosis, or guaranteed outcome.

Support not yet mapped

Mechanism map (working model)

A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.

1

Input or intervention

Nutrigenomics

2

Biological pathway

genomics pathway shaped by dose, context, and individual response

3

Measurable signal

Genotype-informed diet and behavior hypotheses.

4

Boundary

Genotype determinism and privacy misuse.

Research appraisal checklist

Evidence to prioritize

Mechanistic work plus independent replication, well-described human feasibility or clinical studies, regulatory context, and long-term safety evidence.

Outcome anchor

Treat mechanism, model performance, and surrogate movement as intermediate signals until they connect to durable human function or health outcomes.

Main uncertainty

The main uncertainty is product and process integrity: identity, delivery, potency, off-target or immune effects, manufacturing, and long-term surveillance.

What would change the conclusion

Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.

Minimum diligence questions

  • Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
  • Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
  • Can the result be reproduced independently, and does it justify the level of risk being discussed?

Application and translation pathway

Current application boundary

Nutrigenomics is currently best understood as a experimental genomics domain; practical use should stay within the evidence and safety boundary described in this dossier.

Research and applied uses

  • Measurement and hypothesis testing in genomics
  • Protocol design with defined outcomes and context
  • Low-risk applied experimentation with reversible changes

A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.

Question

Define the population, intervention, comparator, and outcome before interpreting a signal.

Signal

Check measurement validity, adherence, confounding, and whether the result repeats.

Function

Ask whether the change improves meaningful daily function or clinical outcomes.

Boundary

Preserve normal functioning and stop when symptoms or risk increase.

Research and clinical readout

Research status

Nutrigenomics has clear promise in subgroup interpretation but limited direct consumer generalizability.

Signal confidence

Grade C (Variable by trait, ancestry data quality, and outcome specificity.)

Key question

Which traits have reliable, reproducible genotype-response links for nutrition?

Clinical perspective

Genotype context can be informative when combined with phenotype, history, and clinician review.

Clinical uncertainty

How far genotype interpretation should drive routine optimization recommendations.

Community patterns

Interest remains high, especially in response prediction and food sensitivity framing.

Common community failure mode

Converting genotype signals into simplistic rule books.

Where this is heading

Population-scale, ancestry-diverse replication will likely determine practical reliability.

What to track next

Genotype-informed diet and behavior hypotheses.

Protocol and safety scaffold

Risk gate: Keep the protocol exploratory, conservative, and reversible; do not infer safety from novelty or popularity.

Baseline first

  • Define one meaningful outcome and a comparison window before changing the protocol.
  • Record relevant symptoms, sleep, workload, medications, and confounders at baseline.

Implementation pattern

  • Change one variable at a time and use the smallest meaningful intervention.
  • Predefine review, washout, and escalation criteria before looking at results.

Monitor

  • Track the target outcome alongside symptoms, function, and adherence.
  • Check data quality and context before treating a change as a signal.

Pause or stop rules

  • Pause for new or worsening symptoms, reduced normal function, or a meaningful safety concern.
  • Pause signal: Deterministic interpretation of one SNP.

Clinician gate

Use clinician review for persistent symptoms, medication changes, abnormal results, pregnancy, or a diagnosed medical condition.

Controversies to monitor

Controversies

  • Single-gene interpretation framing.
  • Privacy and data use concerns outside care settings.

Core reference classes

Research classes

  • Nutrigenomic reproducibility reviews
  • Clinical dietary personalization evidence

Evidence timeline

Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.

2026

Gut Microbial Dysbiosis and Psychiatric Disorders

Frontiers in Neuroscience / PubMed Central - Systematic review

A 2026 systematic review reports candidate microbiome signatures across psychiatric conditions while emphasizing the need for standardized methods, longitudinal work, and validation before diagnostic use.

View source record
2026

Probiotic and Postbiotic Strains in Adults With Mild Anxiety

Nutrients / PubMed - Randomized double-blind placebo-controlled trial

A 2026 trial evaluated live probiotic and heat-treated postbiotic preparations in healthy adults with self-reported anxiety and mild stress, measuring mood, perceived stress, sleep, cortisol, gastrointestinal symptoms, and microbiome changes.

View source record
2025

Multi-Omic Integration for Early Prevention in Healthy Individuals

Frontiers in Molecular Biosciences / PubMed - Cross-sectional integrative omics cohort study

A multi-omic cohort study integrated genomics, urine metabolomics, and serum metabolomics/lipoproteomics in 162 individuals without diagnosed disease and identified molecular subgroups for exploratory risk stratification.

View source record
2024

Prebiotic and Probiotic Interventions in the Gut Feelings Trial

Nutritional Neuroscience / PubMed - 2×2 factorial randomized controlled trial

A factorial randomized trial in 118 adults with low mood and potential for dietary improvement tested a prebiotic-rich diet, probiotic supplementation, and their combination while measuring cognitive outcomes.

View source record

Topic assessment

These questions test evidence interpretation and safety boundaries, not personal medical decisions.

1. What is the most defensible first question when evaluating Nutrigenomics?

  1. What outcome, evidence, and risk boundary are defined?
  2. How quickly can the protocol be intensified?
  3. How many testimonials support it?
Show answer and explanation

What outcome, evidence, and risk boundary are defined?

A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.

2. What would make a claim about Nutrigenomics more trustworthy?

  1. Replication with appropriate controls, context, and meaningful outcomes
  2. A more technical-sounding mechanism
  3. A single positive metric without follow-up
Show answer and explanation

Replication with appropriate controls, context, and meaningful outcomes

Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.

Editorial update history

This log records what changed in the encyclopedia record and why the update matters for interpretation.

2026-08-17 - Foundation release

A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.

2026-08-17 - Evidence ledger update

Added current records spanning real-world digital cohorts, multi-omics, serum proteomics, sweat biosensing, peptides, aging clocks, kinase signaling, endocrine research, personalized nutrition, microbiome response, neurotechnology, and caloric restriction.

Related record update: Multi-Omic Integration for Early Prevention in Healthy Individuals

Linked evidence records

Gut Microbial Dysbiosis and Psychiatric Disorders

Frontiers in Neuroscience / PubMed Central • Systematic review • Published: 2026 • Checked: Aug 17, 2026

A 2026 systematic review reports candidate microbiome signatures across psychiatric conditions while emphasizing the need for standardized methods, longitudinal work, and validation before diagnostic use.

How to interpret this record

What it supports

Microbiome patterns are being studied as candidate associations with psychiatric conditions and gut-brain signaling.

Major limitations

Observational designs, diet, medication, geography, and assay differences can confound microbial signatures.

What it does not establish

A microbiome profile is not a psychiatric diagnosis or proof that a probiotic will correct it.

Learn to read effect sizes and study limits →
Open systematic review

Probiotic and Postbiotic Strains in Adults With Mild Anxiety

Nutrients / PubMed • Randomized double-blind placebo-controlled trial • Published: 2026 • Checked: Aug 17, 2026

A 2026 trial evaluated live probiotic and heat-treated postbiotic preparations in healthy adults with self-reported anxiety and mild stress, measuring mood, perceived stress, sleep, cortisol, gastrointestinal symptoms, and microbiome changes.

How to interpret this record

What it supports

The trial directly tests defined live and inactivated microbial preparations against placebo across mood, stress, sleep, cortisol, gastrointestinal, and microbiome outcomes.

Major limitations

Effects are strain- and population-specific, and microbiome, symptom, and biomarker outcomes may not move together; independent replication remains important.

What it does not establish

A probiotic or postbiotic blend is not a general anxiety treatment, diagnostic, or guaranteed gut-brain intervention.

Learn to read effect sizes and study limits →
Open randomized double-blind placebo-controlled trial

Prebiotic and Probiotic Interventions in the Gut Feelings Trial

Nutritional Neuroscience / PubMed • 2×2 factorial randomized controlled trial • Published: 2024 • Checked: Aug 17, 2026

A factorial randomized trial in 118 adults with low mood and potential for dietary improvement tested a prebiotic-rich diet, probiotic supplementation, and their combination while measuring cognitive outcomes.

How to interpret this record

What it supports

The factorial design can separate some prebiotic, probiotic, and combined intervention effects on cognition in adults with low mood and diet-improvement potential.

Major limitations

Dietary changes, baseline mood, adherence, and strain-specific effects complicate attribution and generalization.

What it does not establish

One factorial trial does not validate a universal microbiome diet, probiotic stack, or cognitive-enhancement protocol.

Learn to read effect sizes and study limits →
Open 2×2 factorial randomized controlled trial

Multi-Omic Integration for Early Prevention in Healthy Individuals

Frontiers in Molecular Biosciences / PubMed • Cross-sectional integrative omics cohort study • Published: 2025 • Checked: Aug 17, 2026

A multi-omic cohort study integrated genomics, urine metabolomics, and serum metabolomics/lipoproteomics in 162 individuals without diagnosed disease and identified molecular subgroups for exploratory risk stratification.

How to interpret this record

What it supports

Integrated genomic and metabolomic profiles can generate hypotheses about molecular subgroups and candidate prevention signals in people without diagnosed disease.

Major limitations

The study is cross-sectional for its main cohort, subgroup models require external validation, and molecular stratification may not translate into actionable benefit.

What it does not establish

A multi-omic cluster is not a diagnosis, a deterministic risk label, or a personalized treatment plan.

Learn to read effect sizes and study limits →
Open cross-sectional integrative omics cohort study